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Abstract 
Human leishmaniasis is a vector-borne  diseases, caused by the Leishmania parasite and endemic in 
100 countries, including southern Europe. The clinical spectrum of Leishmania infection ranges 
from asymptomatic to visceral leishmaniasis (VL), the latter being fatal if not treated. The real 
prevalence of asymptomatic infections is unknown, the diagnosis of VL is challenging and lacks 
standardized methods, and also antileishmanial treatment has critical limitations.  
In this scenario, this study aimed (1) to determine the prevalence of asymptomatic infections in 
blood donors of the Bologna province, where increase of VL cases has been recently reported, (2) to 
compare the performance of nine different serological tests in the diagnosis of VL in northern Italy, 
(3) to assess the antileishmanial activity of a library of newly synthesized natural like compounds, 
ie chalcones. 
(1) The screening on samples of  blood donors living in the Bologna province, shows a total 
prevalence of asymptomatic Leishmania infection of 11.5%, suggesting a high circulation of the 
parasite in this area.   
(2) Our findings on serodiagnosis indicate that rK39 immunochromatographic tests are 
insufficiently sensitive as screening tests for VL, ELISA exhibited suboptimal results in terms of 
sensitivity, IFAT and WB exhibited excellent sensitivity, but their cost and complexity in execution 
would not allow their employment as screening tests for VL. These results confirm  the complexity 
of VL serodiagnosis and reveal  the variability of diagnostic performance of serological tests.  
(3) Screening of 33 newly synthesized chalcones on proliferation of Leishmania promastigote and 
amastigote revealed that 2 compounds showed a remarkable antileishmanial potency against the 
parasite, a low citotoxicity against mammalian cells and they also were able to efficiently bind 
trypanothione reductase - a specific parasite enzyme - suggesting that these compounds should be 
further evaluated as antileishmanial agents. 
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Epidemiological, diagnostic and drug discovery studies of an emerging infection: 
human leishmaniasis 
1. Introduction 
Leishmaniasis is one of the most important neglected tropical diseases, which is endemic in around 
100 countries including Southern Europe, Asia, Africa, and Latin America, with more than 350 
million people living at risk of developing one of the many forms of the disease (1). The presence 
of leishmaniasis is linked to poverty, but social, environmental and climatologic factors also 
influence the disease's epidemiology. In the last decades leishmaniasis has spread in industrialized 
countries and, as a consequence of global warming, in countries previously regarded unfitting for 
the spread of the microorganism (2-4). 
Leishmaniasis is caused by digenetic protozoa parasite from over 20 Leishmania species and is 
transmitted to humans by the bite of infected female phlebotomine sandflies (5). The clinical 
spectrum ranges from asymptomatic infections to three different manifestations: cutaneous 
leishmaniasis (CL), mucocutaneous or mucosal leishmaniasis (ML) and visceral leishmaniasis 
(VL), the latter being the most severe form, which affects internal organs and in the absence of 
specific therapy is fatal (6). 
 
1.1 The Parasite 
The genus Leishmania (L.) is composed of protozoa belonging to the Trypanosamatidae family, 
order Kinetoplastida. There are two subgenera of medical importance that were created on the basis 
of the parasite developmental patterns within the sandfly gut: Leishmania (all development anterior 
to the pylorus) and Viannia (developing in the hindgut and pylorus) (7).  
Initially, species classification was based on various extrinsic criteria such as clinical, geographical 
and biological characteristics. Since the 1970s, intrinsic criteria such as immunological, 
biochemical and genetic data have been used to define species of Leishmania. Today, on the basis 
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of isoenzyme analysis of the parasite (multilocus enzyme electrophoresis - MLEE), leishmanial 
species are grouped into complexes (FIG.1) which are distributed in countries based on 
epidemiology and clinical characteristics (8, 9).  
Leishmania subgenus includes the following complexes 
- L. donovani complex, causing visceral and cutaneous forms in the Old World (species: L. chagasi; 
L. infantum; L. donovani) 
- L. major complex, causing cutaneous forms in the Old World (species: L. major) 
- L. tropica complex, causing disseminated cutaneous forms in the Old World (species: L. 
aethiopica; L. tropica) 
- L. mexicana complex, causing cutaneous and mucosal forms in the New World (species:  L. 
mexicana; L. amazonensis; L. ganhami) 
Viannia subgenus includes the following complexes: 
- L. braziliensis complex, causing mucocutaneous forms in the New World (species:  L. braziliensis; 
L. peruviana) 
- L. guyanensis complex, causing disseminated cutaneous forms in the New World (species: L. 
guyanensis; L. panamensis).  
 
 
 
 
 
9 
 
 
Fig. 1 Taxonomy of the Leishmania genus based on MLEE analysis. Modified from Van der Auwera G. et al., 2015  
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1.1.2 Morphology and life cycle 
These protozoa have a complex digenetic life cycle, maintaining their life cycle through 
transmission between an insect (phlebotomine sandfly) and a mammalian host. Depending on the 
species, transmission can be zoonotic or anthroponotic. In the anthroponotic cycle, the sole 
reservoirs are humans with symptomatic or asymptomatic infections, while the zoonotic cycle 
involves a vector and wild and/or domestic animals as reservoirs, and humans are considered 
accidental hosts (10) (FIG 2).  
The extracellular flagellated, 15-20 m long motile forms of Leishmania spp. are called 
promastigotes (FIG 3a). They are found within the midgut of the sandfly and progress through 
various morphologically distinct stages of differentiation to ultimately become the non-dividing, 
infectious ‗metacyclic‘ promastigotes located at the stomodeal valve (an invagination of the foregut 
into the midgut). During blood feeding, the sandfly regurgitates metacyclic promastigotes, together 
with immunomodulatory parasite-derived proteophosphoglycans and various salivary components. 
Metacyclic promastigotes are phagocytosed by tissue-resident macrophages and dermal dendritic 
cells (DCs) of the host. Inside the monocyte-macrophages, promastigotes transform into the 
amastigote life form. Amastigotes do not have an exteriorized flagellum, are 3-5 m long (FIG. 3b) 
and live as obligate intracellular parasites in mammalian cells: they develop and replicate within the 
phagolysosomal niche of the phagocyte until they are released by cell lysis in order to infect other 
macrophages (11). Amastigotes re-transform into flagellate forms in sandfly midgut after a blood 
meal, completing the transmission cycle (3, 7, 12). A typical characteristic of the parasite is the 
kinetoplast, a structure consisting of mitochondrial DNA that is separated from the nucleus (7). 
Depending on the species tropism, parasites remain localized at the inoculation site, resulting in the 
development of CL, they can spread to mucosae (MCL) or to the organs of the mononuclear 
phagocytic system, giving rise to VL. 
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a            b 
Fig. 3 The two forms of the Leishmania parasite. Schematic diagram of a  promastigote  (a)  and  amastigotes (b)  
within a macrophage. Modified from University of Wisconsin (hhttp://www.uwlax.edu/Biology/Zoo-lab/Lab-3—
Protozoans) and  CDC (https://www.cdc.gov/dpdx/leishmaniasis/index.html) 
 
  
 
 
                                       
Fig.2 Leishmania life cycle. Modified from Kaye P. et al., 2011  
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1.2. The vector 
The blood-feeding phlebotomine sandflies belonging to the genus Phlebotomus in the Old World 
and Lutzomyia in the New World, are considered the only natural vectors of leishmanial species. 
Among the 800 known sandfly species, around  ninety three have been positively identified as 
vectors of leishmaniasis (7, 9). Like mosquitoes, the female needs a blood meal for egg 
development and only the female is hematophagous. The sandfly is a noiseless 2-3 mm long 
arthropod, whose colour ranges from black to white and unlike other Diptera species 
characteristically positions its wings at an angle to the abdomen (7, 13). Adults are mainly active in 
the evening, at night and in the early morning; they are weak flyers with flight speed <1 m/s and 
flight range of a few hundred meters (14, 15). 
Sandflies are widely distributed in Asia, Africa, Australia, Central and South America and Europe. 
The geographical distribution and density of the phlebotomine sandflies are strongly linked to 
environmental conditions such as altitude, land cover, vegetation, climatic factors and to the 
availability of suitable hosts (16). Sandflies are abundant in the Mediterranean basin, the most 
prevalent phlebotomus species are P. perniciosus, P. tobbi, P. ariasi, P. papatasi, P. perfiliewi, P. 
sergenti and P. neglectus (17). 
The sandfly species reported in Italy includes P. perniciosus, P. perfiliewi, P. neglectus and 
P.ariasi.  P. perniciosus and P. neglectus are the most prevalent species observed in central Italy, in 
pre-Alpine territories and in southern Italy; while  P. perfiliewi is the most prevalent species in 
northeastern Italy and P.ariasi is found close to the French border.   
Transmission routes other than insects have rarely been reported, such as vertical transmission and 
injection by needles – the latter led to a VL outbreak in the ‗90 among  intravenous-drug users in 
southern Europe (18, 19). Potential transmission of Leishmania by organ transplantation, blood 
transfusion and semen has  also been reported (19-24).  
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1.3 The reservoir hosts 
For vector-borne infections, the system comprises one or more vectors and one or more mammalian 
hosts, which allow the agent to be transferred continuously between them (25). A mammal host 
responsible for the long-term maintenance of a population of infectious agents is called a reservoir 
host. The reservoir spectrum that maintains the various species of Leishmania is wide; within the 
zoonotic leishmaniases the reservoir hosts are wild animals, commensals or domestic animals (17, 
26, 27). Dogs are the main domestic reservoirs, with widespread dissemination of parasites both in 
viscera and dermis, but also foxes, jackals and wolves represent sylvatic reservoirs of L. infantum, 
L. major and L. aethiopica. Rodents, bradypus and foxes are reservoirs of Leishmania  in the New 
World. Within anthroponotic leishmaniases, the reservoir host is human (6), who is directly 
involved as principal reservoir host in VL caused by L. donovani and CL caused by L. tropica. 
 
1.4 Epidemiology 
Leishmaniasis is still one of the world‘s most neglected diseases. The disease affects the poorest 
people on earth and is associated with malnutrition, population displacement, poor housing, a weak 
immune system and lack of financial resources (6, 28). About 350 million people are considered at 
risk of contracting leishmaniasis and 2 million new cases occur yearly. Control programs are 
insufficient and morbidity/ mortality from leishmaniasis worldwide show a worrying increasing 
trend (6). 
Leishmaniasis is distributed worldwide with the exception of Australia and Antarctica. Within the 
Old World it is spread in Asia, the Middle East, Africa and the Mediterranean basin. Within the New 
World cases of leishmaniasis have been recorded from the southern United States to northern 
Argentina, with the exception of the Caribbean islands, Chile and Uruguay (6, 7). 
It is estimated that about 75% of the total cases of CL are concentrated within 10 countries, 4 of 
which are in the Americas (Brazil, Colombia, Peru, and Nicaragua). With respect to VL, 90% of 
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cases are concentrated within Brazil, Ethiopia, India, Bangladesh, Sudan, and South Sudan (29, 30). 
Almost 90% of MCL cases occur in Bolivia, Brazil and Peru (6). 
In southern Europe leishmaniasis is endemic in Spain, Portugal, Greece, France, Italy and the 
Balkans. Most of the reported cases are due to zoonotic VL, CL is also present (2), but there are 
probably many more cases than those registered (31). Human leishmaniasis appears not to be 
limited to the Mediterranean region anymore, it has spread northward (where sandflies were 
previously thought to be absent or present only in very low densities), as shown by the recent 
reports in northern Italy and one case in southern Germany (2, 32-34). 
 
1.5 Pathogenesis 
The diverse clinical manifestations of Leishmania, from cutaneous lesions to systemic VL, are the 
result of the interplay between the infecting parasitic species and the host‘s immune response. 
Parasites such as L. major are mainly dermotropic and remain contained at cutaneous levels, while  
L. infantum and L. donovani may disseminate  into the organs (35, 36). 
The sandfly lacerates blood vessels during feeding and parasites are introduced intradermally. 
Neutrophils are the earliest cells recruited to the site of the sandfly bite and represent the first 
infected cell population(37, 38). Parasites are taken up essentially by dendritic cells and 
macrophages that can then leave the injection site. The types of macrophage population infected by 
the cutaneous and visceral Leishmania species differ, possibly depending on the preferential affinity 
of the parasite to specific macrophage cell surface receptors, however the mechanism is still poorly 
understood. 
Antileishmanial immunity is mediated via both innate (macrophages, dendritic cells and 
neutrophils) and adaptive (T cells) immunity, but the CD4+ T-cell subset is crucial for host defence. 
In addition, cytokines participate in a network of interactions that induce and control the immune 
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responses. Conversely, although a strong humoral response is present during the infection, it 
appears that antibodies play no role in protection (39).  
Based on experimental studies in murine models, it is widely accepted that resistance to the disease 
is correlated with expansion of T-helper-1 (Th1) cells that produce IL-2 and IFN-γ and amplify 
effector response by activating macrophages to inhibit the growth of the parasite. The development 
of T-helper-2 (Th2) cells, resulting in IL-4, IL-5 and IL-10 production, or a mixed Th1/Th2 
response is associated to disseminated infection (40-42)  
Polymorphisms in genes involved in such immune interactions may play a role in the clinical 
pleiomorphism demonstrated by leishmaniasis (7). Furthermore, acquired immunosuppressive 
conditions can modulate parasite replication.  For example, it was observed that infection with HIV-
1 leads to 100–2,230 times increase in the risk of developing VL (43). HIV/Leishmania coinfection 
include chronic evolution, with a high rate of relapse and poor response to treatment (7, 44, 45). 
1.6 Clinical presentation 
The clinical spectrum of leishmaniases depends mostly on parasite species and host immune 
response, ranging from asymptomatic infection (80-95% of affected people) to three main clinical 
forms: visceral (also known as kala-azar and the most severe form of the disease), cutaneous and 
mucocutaneous (20, 46). The incubation period between the infecting sandfly bite and symptoms‘ 
onset ranges from 1 week – 2 months to a year or more (6). 
1.6.1 Visceral leishmaniasis (VL) 
VL is caused by parasite belonging to the Leishmania donovani complex and is associated with 
considerable morbidity and mortality. VL is endemic in around 100 countries including Southern 
Europe, Asia, Africa, and Latin America. More than 90% of new cases reported to WHO occurred 
in 6 countries: Brazil, Ethiopia, India, Somalia, South Sudan and Sudan. 
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VL is the most severe form of the disease and is fatal if untreated. It is characterized by irregular fever, 
weight loss, splenomegaly, hepatomegaly and anaemia (FIG. 4) (6). Parasites proliferate wherever 
there are cells of the mononuclear phagocyte system, most often in macrophages; Bone marrow 
cells become infected, and patients develop pancytopenia and immunosuppression, making them 
susceptible to bacterial superinfections (47). 
 
Fig.4 Hepatosplenomegaly in a VL case. Modified fromhttp://www.emedmd.com/content/leishmaniasis 
 
1.6.2 Tegumentary leishmaniasis (CL and MCL) 
CL usually occurs in an exposed area accessible to sandflies such as the face, neck and limbs. In the 
Old World it is caused by parasites belonging to the Leishmania major complex,  L. tropica 
complex and occasionally by L. infantum (L. donovani complex). In the Americas, CL is most 
commonly caused by the species Leishmania mexicana, Leishmania braziliensis, or Leishmania 
panamensi. L. major and L. tropica tend to cause less severe lesions that heal more quickly, and 
therefore, take on a relatively benign course (46). Conversely, CL in the New World is less likely to 
resolve without treatment. 
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Regardless of the infecting parasite species, CL is not a life threatening disease, but healing occurs 
over several months  and may leave a scar and permanent alterations in the skin pigmentation. 
Lesions may begin as small red papules and can progress into erythematous nodules, indurated 
plaques, scaly plaques or ulcers with raised, rolled dusky borders; they may be dry and crusted or be 
accompanied by exudates (FIG. 5a) (48). 
MCL is usually caused by leishmanial species of the New World, but it has occasionally been 
associated with any species that are endemic in the Old Word (49, 50). In the New World, MCL 
usually begins with a cutaneous lesion that may be followed by metastasis to the mucosal tissues of 
the mouth and upper respiratory tract and may result in severe tissue destruction and gross 
disfigurement (7). Studies have shown that MCL can present from several months to 20 or more 
years after a cutaneous lesion. Mucosal lesions caused by L.infantum are not associated to a 
previous CL and involve the buccal or laryngeal mucosae in immunocompetent or 
immunocompromised patients (FIG. 5b)(51). 
 
 a    b 
Fig.5 (a) nodular lesion of cutaneous leishmaniasis  (b) ulceration of the oral mucosa in mucosal leishmaniasis. 
Modified from Nangia A. et al., 2014 
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1.6.3 Leishmaniasis in immunocompromised patients 
Immunosuppression is one of the strongest risk factor responsible for increased vulnerability to a 
primary Leishmania infection and to reactivation of a latent infection.  Immunosuppression can also 
alter disease presentation and treatment response. While historically mainly observed in HIV-
infected patients, non-HIV related immunosuppressive conditions are becoming increasingly 
prevalent globally, mainly because of better medical care of patients with chronic illnesses and the 
therapeutic use of immunosuppressive drugs as TNF-alpha antagonists (52-54). VL has also been 
reported after organ transplantation (52, 55). A comparative study of HIV-infected and uninfected 
Spanish individuals showed that AIDS patients have an incidence of VL that is 418-fold higher than 
HIV-negative individuals (56). 
It has been shown that HIV and Leishmania infection reinforce each other, HIV patients are more 
likely to develop VL, due to reactivation of a dormant infection or clinical manifestation after 
primary infection (6). At the same time, VL promotes the clinical progression of HIV disease and 
the development of AIDS-defining conditions and negatively affects the response to antiretroviral 
treatment (57). Patients characteristically have high disseminated parasite loads and the infection is 
difficult to cure (58, 59). 
 
1.6.4 Asymptomatic infections 
Asymptomatic forms characterize individuals infected by the parasite in apparently healthy 
condition. Actually, the majority of infected people do not progress to patent leishmaniasis;  clinical 
syndromes caused by Leishmania are only the tip of the iceberg.  Several prospective studies have 
documented the ratio of asymptomatic infections with L. donovani or L. infantum infection to 
incident clinical cases as 4:1 in Kenya, 4:1 in Bangladesh, 6:1 in Ethiopia, 9:1 in India and Nepal 
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18:1 in Brazil and 50:1 in Spain, suggesting that many people infected with Leishmania develop an 
effective immune response and do not manifest clinical disease (60-63). 
 
 
Fig. 4 Human leishmaniasis pyramid and possible involvement of asymptomatic carriers in transmission of 
leishmaniasis. Modified from Michael G. et al., 2011  
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1.7 Diagnosis 
Microbiological diagnosis of leishmaniasis is fundamental because symptoms are not 
pathognomonic. For identification of leishmaniasis, clinical suspects must be linked to a positive 
parasitological and/or serological test (6).  
1.7.1 Diagnosis of visceral leishmaniasis 
The diagnosis of VL remains challenging, due to the limited sensitivity of microscopy, the poor 
performance of serological methods in immunocompromised patients and the lack of 
standardization of molecular tests (64). 
The diagnosis of VL is traditionally based on serologic testing and the direct demonstration of 
Leishmania by microscopic examination of bone marrow aspirates, but limits have to be considered, 
including low sensitivity of serologic testing in immunosuppressed patients, the necessity to use 
invasive procedures to obtain bone marrow samples, the low sensitivity of microscopy examination 
(between 53% and 85%) and the need of expert microscopists (65). Over the past 10 years, 
molecular tests have been developed, and polymerase chain reaction (PCR) represents a highly 
sensitive technique for the diagnosis of VL (64, 66).  
1.7.1.1 Serological testing for VL  
Serologic diagnosis is based on the presence of a specific humoral response. Current serological 
tests available for routine use are employing different techniques, including indirect 
immunofluorescence test (IFAT), enzyme-linked immunosorbent assay (ELISA), western blot 
(WB) and direct agglutination test (DAT). All antibody detection tests share the same drawbacks: 
antibodies remain positive for months after the patient has been cured and do not differentiate 
between current and past infection (67). Further, serological tests may give false negative results in 
immunocompromised patients.  
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IFAT, ELISA and WB exhibit excellent diagnostic accuracy, but their cost and complexity in 
execution would not allow their employment in developing countries. Therefore, DAT and 
immunochromatographic tests (ICT) have been produced.  
IFAT is based on detecting antibodies, which are demonstrable in the early stages of infection,. It 
has shown acceptable estimates for sensitivity (87–100%) and specificity (77–100%) (68). IFAT is 
based on immunological detection of anti-Leishmania antibodies in human serum: using a slide 
with promastigotes fixed on it as antigens and fluorescein-labeled anti-human immunoglobulins.  
ELISA is one of the preferred laboratory test for serodiagnosis of VL (68). ELISA is a test for the 
qualitative determination of specific IgG against Leishmania in human serum: on the surface of the 
microtiter wells, inactivated soluble antigens of Leishmania are bound, the human serum anti-
Leishmania antibodies possibly present in the sample bind with the antigens. A peroxidase 
conjugated antibody (anti-IgG) with a substrate and a chromogen are added, the bound converts the 
colorless substrate/chromogen to colored one and the absorption is measured. The sensitivity and 
specificity of ELISA depends on the antigen used; one of the most commonly used antigens is a 
crude soluble antigen (CSA). The sensitivity and specificity of ELISA using CSA range from 80 to 
100% and from 84 to 95%, respectively. 
ICT rK39 rapid test is a non-invasive and cost effective method that has shown high sensitivity and 
specificity in the Indian subcontinent and southern Europe (68), while in East Africa the estimated 
sensitivity seems to be lower (69, 70). It is a qualitative test for the detection of antibody to 
Leishmania in serum. The membrane is pre-coated with recombinant parasitic rk39 antigen. During 
testing, the serum sample reacts with the dye conjugate which has been pre-coated in the test 
device. The mixture then migrates upward on the membrane chromatographically by capillary 
action to react with recombinant Leishmania antigen on the membrane and generate a line (71). 
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DAT is an inexpensive and simple-to-perform test, making it ideal for both field and laboratory use. 
DAT is based on direct agglutination of Leishmania promastigotes that react specifically with anti-
Leishmania antibodies in the serum specimen, resulting in agglutination of the promastigotes. 
Whole, trypsinized, Coomassie-stained promastigotes can be used either as a suspension or in 
freeze-dried form that can be stored at room temperature for at least two years (67). DAT is 
considered to be a highly sensitive and specific method: according to a meta-analysis that included 
30 studies, the sensitivity and specificity of DAT were estimated at 94.8 and 97.1%, respectively 
(68). 
For the WB, promastigotes are cultured to log phase, lysed, and the proteins are separated on SDS-
PAGE. The separated proteins are electrotransferred onto a nitrocellulose membrane and probed 
with serum from the patient. This technique provides detailed antibody responses to various 
leishmanial antigens, and has been found to be more sensitive than IFAT and ELISA, especially in 
co-infected HIV patients with VL, but the drawbacks of the technique (equipment and time 
requirements, cumbersomeness, and cost) limit its use to research laboratories or reference 
laboratories (67, 72). 
1.7.1.2 Direct testing for VL 
Parasitological diagnosis can be performed by demonstrating the amastigote form of the parasite in 
tissues, isolating the parasite in cultures, or by  molecular assays.  
Amastigotes can be observed within macrophages on microscopic examination of Giemsa-stained 
bone marrow aspirate specimens. The specificity of the method is high, while the sensitivity varies 
according to the examined aspirates. Clinical samples (bone marrow aspirate or buffy coat from 
peripheral blood from HIV positive patients) may also be cultured into monophasic (Schneider‘s 
insect medium, M199, or Grace‘s medium) or diphasic (Novy-McNeal-Nicolle medium and Evans 
modified Tobie‘s medium) culture media. Cultures should be examined weekly for four weeks and 
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promastigotes are observed in case of positive culture. Culture from splenic biopsy and from bone 
marrow aspirates possesses high specificity, nevertheless this technique is tedious, time consuming, 
requires expertise, expensive equipment and is, therefore, restricted to referral laboratories and 
hospitals (68). 
Molecular techniques can detect nucleic acids unique to the parasite; a variety of nucleic acid 
detection methods targeting both DNA and RNA have been developed. Amongst these, PCR has 
proved to be a highly sensitive and specific technique, especially in immunosuppressed patients. 
This method is minimally invasive as peripheral blood specimens are required, is capable of 
identifying relapses/reinfections in VL-treated patients, and can provide species identification (73). 
Different target sequences are used, which include ribosomal RNA genes, kinetoplast DNA (kDNA, 
mitochondrion genome), miniexon-derived RNA (medRNA), gp63, G6PD and the β-tubulin gene 
region. Sensitivity is excellent (near 100%) in spleen or bone marrow and can be lower but still 
good by employing peripheral blood (varying from 70% to 100%) (67, 74). However, PCR 
techniques remain complex and expensive to perform, and in most VL-endemic countries this 
technique is not affordable in the diagnostic routine. 
1.7.2 Tegumentary leishmaniasis 
Clinical manifestations of tegumentary leishmaniasis are not specific and may mimic other skin 
conditions, such as staphylococcal or streptococcal infection, leprosy, mycobacterial ulcer, cancer, 
fungal infection, sarcoidosis and tropical ulcer (67, 75). As the clinical presentation of tegumentary 
leishmaniasis lacks specificity and treatment is costly and toxic, diagnostic confirmation is required. 
Diagnosis is obtained microscopically by direct identification of amastigotes in Giemsa-stained 
smears of scraping, fine-needle aspiration or biopsy of lesions. The material obtained by any of 
these methods can be used for microscopic examination, culture and molecular diagnostic 
techniques. A combination of microscopy and culture increases diagnostic sensitivity to more than 
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85% (67). DNA detection by PCR is based on kDNA or rDNA, mini-exon, β-tubulin, gp63, G6PD, 
cytochrome B gene; it offers the best sensitivity and specificity rates (98.8% and 100%, 
respectively) (74), but is not currently practical in disease-endemic areas where technical resources 
are poor (75). 
Serological diagnosis has low sensitivity and variable specificity, it does not distinguish between 
past and present infections; moreover, anti-leishmanial antibodies can be detected by serological 
tests but they tend to be undetectable or present at low titers due to poor humoral response, 
therefore serological assays are not the usual diagnostic methods, because they are of little value in 
the diagnosis of CL; conversely, concerning ML diagnosis, antibody research is useful and shows a 
good sensitivity (6, 67, 75).  
1.8 Treatment  
Different chemical compounds have been found to be effective against leishmanisis; however, most 
are not safe and are difficult to use (76). One of the main challenges is the presence of different 
Leishmania species and various clinical manifestation, complicating the therapeutic approach. 
There are many available anti-leishmanial agents, but the optimal drug is still out of reach, since 
almost all available compounds share several limitations; many of them are expensive with severe 
side and toxic effects or have a marked reduction of therapeutic effectiveness(77, 78).   
1.8.1.1 Pentavalent antimonials 
Pentavalent antimonials have been used  used all over the world since the mid of 1930s for all forms 
of leishmaniasis. Two antimonials are available: meglumine antimoniate (Glucantime®) and 
sodium stibogluconate (Pentostam®). They are chemically similar, and their toxicity and efficacy 
are related to their antimonial content (6).  
Although antimonials are the most commonly used medication against leishmaniasis, their exact 
mechanism of action remains unknown. Several Leishmania-killing mechanisms have been 
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attributed to pentavalent antimonials including apoptosis, disturbance of fatty acids 𝛽-oxidation, 
adenosine diphosphate phosphorylation, and redox balance, inhibition of the glycolysis pathway 
and ability to act on infected macrophages eliciting an oxidative/nitrosative stress against 
internalized parasites (79, 80).  
They are associated with serious adverse side effects, including arthralgias, myalgias, leukopenia, 
pancreatitis, liver toxicity, cardiotoxicity and cardiac arrhythmia in the patients, and increased 
parasite resistance (81). 
1.8.1.2 Amphotericin B 
An alternative drug to the antimonials is the antifungal macrolide, amphotericin B, that has shown 
optimal results on MCL and VL. Two forms of amphotericin are available: conventional 
amphotericin B deoxycholate and liposomal amphotericin B (Ambisome®), the lipid formulations 
of amphotericin B, that have been developed to improve the pharmacokinetic characters of the drug, 
the tolerability in the patient and to minimize the side effects (82).  
Amphotericin B controls Leishmania infections through two distinct mechanisms. The first 
includes, auto-oxidation of amphotericin, leading to the production of free radicals. The second 
mechanism requires the binding of amphotericin to sterols in the membrane of the parasites, which 
makes pores that cause an ion imbalance (80). 
Amphotericin B exhibits high efficacy (90–100%) even in Leishmania/HIV co-infection cases (82). 
However, it is an expensive drug and it has many adverse effects including fever, thrombophlebitis 
and occasionally hypokalemia, nephrotoxicity, liver disorder, myocarditis (83). 
1.8.1.3 Miltefosine 
Miltefosine is an alkyl phosphocholine analogue, originally developed as an oral anticancer drug 
then implicated as anti-leishmanial agent. It is the only oral medication available against VL and 
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CL, with a cure rate of 95%. This drug is well tolerated for the treatment of all forms of 
leishmaniasis (6, 82).  
The mechanism of anti-leishmanial action of miltefosine remains unclear, but parasite apoptosis 
preceded by drug intracellular accumulation has been described. Other possible mechanisms include 
cytochrome c oxidase inhibition, which leads to mitochondrial dysfunction and immunomodulation 
(79). Miltefosine commonly induces gastrointestinal side-effects such as anorexia, nausea, 
vomiting, diarrhea and recent studies have pointed out that miltefosine has a potential teratogenic 
effect (6, 79). 
1.8.1.4 Paromomycin 
Paromomycin is an antibacterial aminoglycoside which has been used for the treatment of VL in a 
parenteral formulation and in both topical and parenteral formulations for the treatment of CL (82, 
84). This dryg has a high efficacy (94.6%) and low price (82).  
Paromomycin can affect ribosomal activity, inhibiting protein synthesis and mitochondrial 
membrane potential, which deprives the parasite of energy, other mechanisms of action were also 
suggested for this drug,  such as alteration on membrane fluidity and lipid metabolism (80, 82). 
Paromomycin showa a low incidence of side effects, including reversible ototoxicity, vestibular 
instability and increase of hepatic transaminases. Renal toxicity is rare (6, 82). 
1.8.1.5 Azoles medicines 
These oral imidazole-derived antifungal agents have variable efficacy in leishmaniasis treatment. 
They have been reported to be effective in the treatment of VL cases, either alone or in association 
with other anti-leishmanial agents (82). Azoles exert their effects through inhibition of some key 
enzymes in the synthesis of ergosterol. Adverse effects include gastrointestinal symptoms and 
hepatotoxicity (84). 
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1.8.2 Treatment of leishmaniasis in immunocompromised patients 
The criteria used to assess response to the antileishmanial treatment in the immunocompetent 
patients are not applicable in the immunocompromised host. as immunosuppressed patients tend to 
have several relapses of VL (85). 
 Leishmaniasis in HIV-positive patients is particularly severe; HIV and Leishmania infection 
reinforce each other, VL negatively affects the response to antiretroviral treatment and is difficult to 
cure in co-infected patients. The co-infection is usually associated with low cure rate, high relapse 
rate and treatment-associated mortality particularly with antimonials (85). The treatment of VL/HIV 
co-infection cases is similar to that of the immunocompetent VL patients with some precautions in 
doses due to low CD4 counts, (combined with leukopenia and lymphocitopenia) and prolonged 
therapeutic regimen., WHO recommends liposomal amphotericin B as a preferred therapy because 
of its safety profile. Miltefosine had an acceptable safety profile, too and combined therapy is often 
recommended (6, 82). 
1.8.3 Anti-leishmanial drug candidates with focus on natural and natural like products 
Given the above mentioned scenario, development of new, less toxic and more cost-effective drugs, 
which could become available for low-income populations to treat the disease has become a 
necessity (81). In recent years, there has been growing interest in alternative natural products and 
plant compounds as promising class of drug candidates against leishmaniasis (79), since these 
products may be safe, effective and economically feasible for the treatment of leishmaniasis. The 
secondary metabolites of plants have been demonstrated to be beneficial against diverse groups of 
pathogens such as viruses, bacteria and fungi. Various herbal formulations and plant secondary 
metabolites such as isoflavonoids, polysaccharides, tannins, indoles and glucans are known to have 
different pharmacological profiles. Some important categories of natural products that have shown 
good or excellent anti-leishmanial properties are the quinones, the alkaloids (i.e. indoles, quinolines, 
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steroidal alkaloids) (86, 87), the terpenoids (i.e. monoterpenes, sesquiterpenes, saponins) (87-91), 
the sterols, the phenolics (i.e. flavonoids, chalcones, coumarins, tannins, lignans) (87, 89). In 
addition, substantial evidence from the literature indicates that essential oils (EO), volatile mixtures 
of compounds obtained from spices, aromatic herbs, fruits and flowers possess a wide spectrum of 
biological activities, among which it has been shown that several EOs, or their constituents, have 
inhibitory activity on Leishmania (92-95). 
Within alkaloids, quinolines isolated from Galipea longiflora have been shown effect against New 
World cutaneous leishmaniasis in BALB/c mice and in vitro activity against the promastigote form 
of Leishmania (96). Indoles have been reported to exhibit significant antileishmanial activities 
against the promastigote form of L. amazoniensis, L. major and L. donovani (97). Steroidal 
alkaloids inhibits the growth of L. amazoniensis, L. donovani and L. braziliensis (97). 
Within terpenoids, monoterpenes shows antileishmanial activity against promastigotes of twelve 
Leishmania species; an in vitro study indicates that the monoterpene linanool also exhibits strong 
antileishmanial activity against intracellular amastigotes (98). Sesquiterpenes have strong inhibitory 
effect against promastigotes of Leishmania and the sesquiterpene endoperoxide isolated from 
Artemisia annua, artemisinin (an established anti-malarial drug), demonstrated anti-promastigote 
activity, anti-amastigotes activity and in vivo activities in a murine model of infection. In fact, in a 
BALB/c model of VL, orally administered artemisinin effectively reduced both splenic weight and 
parasite burden (99, 100). Saponins isolated from Astragalus oleifolius, show notable growth 
inhibitory activity against amastigotes of L. donovani; moreover, none of these compounds 
possesses cytotoxicity on mammalian cells. Saponins obtained from the leaves of Hedera helix and 
Buddleja madagascariensis show leishmanicidal activity against L. infantum and L. tropica. Other 
saponins show potent antileishmanial activity against L. major (101). 
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Within sterols, compounds isolated from the Mexican plant Pentalinon andrieuxii exhibit 
significant in vitro antileishmanial activity against the promastigote and amastigote forms of L. 
mexicana (102). 
Within phenolics, flavonoids seem to be promising drugs candidates for the treatment of all forms 
of leishmaniasis (103). Chalcones have been observed to possess potent antileishmanial activity, 
with strong inhibition of L. major, L. tropica, L. braziliensis , L. donovani, L. amazonensis and L. 
infantum (104, 105). Coumarins are an important class of polyphenolic compounds that shows 
significant in vivo antileishmanial activity against L. amazonensis and L. major (106). Lignans 
show activity against the amastigotes and the promastigotes form of different species (97). 
Despite many compounds from plants and natural products-inspired molecules have shown good 
activity  against Leishmania in vitro and in murine models, due to lack of investments in the field of 
neglected diseases such as leishmaniasis none of them has undergone clinical evaluation (83, 97).  
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2.  Aim of the study  
Human leishmaniasis is spread worldwide, is endemic in around 100 countries including Southern 
Europe, Asia, Africa, and Latin America and causes high morbidity and mortality, but still it is 
included in the neglected tropical diseases, based on the limited resources invested in diagnosis, 
treatment and control, and on its strong association with poverty (4).  
The incidence of human leishmaniasis has displayed a sharp increase since the early 1990s in 
Mediterranean countries of southern Europe. In recent years, a northward spread of leishmaniasis 
has been observed in Mediterranean Europe (2).  
The real prevalence of this parasitic disease is unknown, but it has been demonstrated that clinical 
leishmaniasis cases usually represent the tip of an ―infection iceberg‖; several prospective studies 
have documented that many individuals that are infected with Leishmania do not manifest clinical 
disease, remaining asymptomatic. Nevertheless, data about the real prevalence of asymptomatic 
human carriers are scarce. 
The diagnosis of VL is challenging and lacks standardized methods. Most of data about the 
reliability and accuracy of diagnostic methods are from studies performed in India and Brazil,  not 
reflecting the current situation for leishmaniasis in the Mediterranean Europe. 
Also chemotherapy  has critical limitations, since currently available treatments are toxic, expensive 
and require long term regimens. Further, drug resistant Leishmania parasites are becoming a serious 
problem in the Indian subcontinent. 
In this scenario, this study aimed to: 
- determine the prevalence of asymptomatic infections in a pool of blood donors in the municipality 
of Valsamoggia (Bologna province), where increase of VL cases has been reported in 2013 and 
2014 (study I); 
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- compare the performance of nine different serological tests in the diagnosis of autochthonous VL 
in northern Italy and to determine a valid screening test for serodiagnosis of VL (study II); 
- assess the antileishmanial activity of a library of newly synthesized chalcones, by evaluating the 
ability to affect parasite growth and the affinity of novel molecules toward the parasitic 
trypanothione reductase enzyme, in order to identify novel potential antileishmanial drugs (study 
III). 
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3. Methods 
The research was carried out at the Regional Reference Centre for Microbiological Emergencies 
(CRREM), at the Sant‘Orsola-Malpighi University Hospital of Bologna, Italy. 
3.1 Study I  
3.1.1 Study design 
For the first study there were analyzed samples of blood donors residing in Valsamoggia, an Italian 
district of 30.071 citizens in the Bologna province, Emilia-Romagna region. The study was 
designed as evaluation of the prevalence of asymptomatic carriers residing in Valsamoggia district. 
260 blood donor‘s samples were collected at the CRREM laboratory from 1 April 2014 to 31 March 
2015, none of the donors have shown previous clinical manifestation of VL.  Samples were taken 
from the Transfusion Unit, Maggiore Hospital of Bologna and sent to the CRREM laboratory 
within 5 days from the collection of blood sample. The prevalence of asymptomatic infections were 
evaluated with a serological assay and a molecular assay. 
3.1.2 Serological and molecular tests 
Samples were centrifuge at 1500 rpm for 10 minutes, 500 µl of serum and 300 µl of buffy coat were 
collected for each blood sample then stored at – 20 °C. 
Serological testing was performed by a commercial western blot kit: Leishmania WESTERN BLOT 
IgG – LDBio Dianostics® (Lyon, France). The western blot technique provides detailed antibody 
responses to various leishmanial antigens. 
Specific 14-kDa and 16-kDa proteins of L.infantum are electrotransferred onto a nitrocellulose 
membrane and probed with serum from the patient. The presence on the strip of the bands is 
indicative of the evidence of specific anti-Leishmania IgG in the serum. 
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Home-made molecular methods were used to detect leishmanial DNA in buffy coats. Nucleic acids 
were extracted from 300 µL buffy coat with QIAsymphony SP/AS instruments, Qiagen® (Hilden, 
Germany). DNA was eluted in 200µL of elution buffer. DNA was amplified employing one real-
time PCR assay, (18) that amplifying the kinetoplast(k)DNA (19). Primers (15 pmol of RV1 5‘-
CTTTTCTGGTCCTCCGGGTAGG-3‘, 15 pmol of RV2 5‘-
CCACCCGGCCCTATTTTACACCAA-3‘ for kDNA PCR) were synthesized by PrimmBiotech 
(Milan, Italy) and 50 pmol of TaqManprobes (FAM-TTTTCGCAGAACGCCCCTACCCGC-
TAMRA for kDNA PCR) were synthesized by IDTDNA (Leuven, Belgium). The real-time PCR 
assays were performed by employing the CFX Real Time PCR detection System (Bio-Rad, 
California, USA). β2-microglobulin real-time PCR assay was run simultaneously as a control of 
amplification of the extracted DNA. 
3.2 Study II 
3.2.1 Study design  
This study was designed as a retrospective comparative study of serological methods performed 
on77 human serum samples chosen from those arrived to the CRREM laboratory between 2013 and 
2015. During 2013-2015, samples of patients with suspected VL residing in the Emilia-Romagna 
region were sent to the CRREM laboratory, where microbiological diagnosis of VL was performed 
by molecular and serological methods.  Autochthonous VL was confirmed in 27 out of 77 cases and 
dismissed in the other 50 cases. Specificity, sensitivity, positive predictive value (PPV), negative 
predictive value (NPV) of nine commercial serological assays were evaluated.  Diagnosis of VL 
was established by the case definition of the World Health Organization, which describes a case of 
VL as a patient showing characteristic clinical signs with serological and/or parasitological 
confirmation. Standardized clinical evidence were combined with frontline diagnosis by serology 
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supported by real-time PCR as second line parasitological test. Subsequently, samples were 
archived and stored at – 80 °C. 
3.2.2 Test methods/serological assays 
Index tests included nine serological assays, all of them were commercial products. 
IFAT: Leishmania-Spot IF – BioMérieux® (Marcy l‘Etoile, France). It detects IgG antibodies 
against L.infantum; promastigote form is the antigen, obtainted from in vitro culture, inactivated and 
coated on slides. Samples were considered positive when specific IgG titer was equal or above 
1/160.  
ICT: i) Leishmania Dipstick Rapydtest – APACOR® (Wokingham, England); ii) On Site 
Leishmania IgG/IgM Combo Rapid Test – CTK Biotech ® (San Diego, USA); iii) Leishmania Strip 
Quick Test – CYPRESS Diagnotics ® (Langdorp, Belgium). A qualitative membrane-based 
immunoassay with nitrocellulose strips impregnated with recombinant K39 Leishmania antigen, it 
detects specific antibodies against rK39. Tests were performed according to the 
manufacturers‘instructions. 
ELISA: i) Leishmania ELISA IgG + IgM – VIRCELL Microbiologists® (Granada, Spain); ii) 
Leishmania Ab ELISA – CYPRESS Diagnotics ® (Langdorp, Belgium); iii) Leishmania infantum 
IgG – ELISA - NOVATECH® (Bologna, Italy); iv) Leishmania Ab - RIDASCREEN® (Darmstadt, 
Germany). 
Tests were performed according to the manufacturers‘instructions. For the detection of antibodies 
all tests used soluble inactivated antigens of L.infantum. OD were determinated at 450 nm, Samples 
were classified as positive, negative, or indeterminate according to the manufacturers‘cut off values. 
WB: Leishmania WESTERN BLOT IgG – LDBio Dianostics® (Lyon, France). The western blot 
technique provides detailed antibody responses to various leishmanial antigens. 
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Specific 14-kDa and 16-kDa proteins of L.infantum are electrotransferred onto a nitrocellulose 
membrane and probed with serum from the patient. The presence on the strip of the bands is 
indicative of the evidence of specific anti-Leishmania IgG in the serum. 
3.3 Study III 
3.3.1 Study design 
Thirty-three newly synthesized chalcones have been screened to assess their anti-leishmanial 
potential. The study was designed as analysis of synthetic natural product-inspired molecules as 
anti-leishmanial candidates, by evaluating the ability to affect parasite growth and to inhibit the 
protozoan enzyme trypanothione reductase (TR), an essential enzyme for Leishmania metabolism, 
that is not present in human cells. 
3.3.2 Chalcone synthesis 
All the chalcone derivatives used in the present study have been readily synthesized through the 
classic base-catalyzed Claisen-Schmidt procedure. In particular, the selected acetophenone was 
reacted at room temperature with the appropriate aldehyde in ethyl alcohol and in the presence of a 
50% KOH/H2O solution, to give the desired final compounds. The acetophenone intermediates 
were obtained by reaction of 2,4-dihydroxyacetophenone with the appropriate alkyl bromide to 
obtain the 2-OH,4-alkoxyacetophenones;reaction with methyl iodide allowed obtaining the 2-
methoxy,4-alkoxyacetophenones. 
3.3.3 Drug susceptibility tests 
Promastigote forms of reference strain of L. donovani (MHOM/NP/02/BPK282/0cl4) were cultured 
at 26°C in a liquid custom made medium. Cell culture THP1 (human leukemia monocytic cell line), 
used for the anti-amastigote assay, were cultured at 37°C in liquid medium. Cell culture VERO 
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(kidney of African green monkey cell line), used for the cytotoxicity assay, were cultured at 37°C in 
liquid medium. 
The promastigote growth inhibition assay was carried out incubating promastigotes in 96-well 
plates with tested compounds (at micromolar concentration, range 40 µM – 1.5 µM), the effect of 
the chalcones was evaluated by the AlamarBlue® assay (Thermo Fisher Scientific, Massachusetts, 
USA). To estimate the concentrations at which compounds cause 50% inhibition of growth (IC50) 
the AlamarBlue method based on monitoring the reducing environment (reduction of resazurin into 
fluorescent resorufin) of proliferating cells was employed and absorbance was measured at 550 nm 
and 630 nm.  
For the anti-amastigote assay, human acute monocytic leukemia cell line (THP1) infected with 
promastigotes was used. Cells were seeded in a 96-well plate, after 48 h promastigotes were 
inoculated, phagocytized and transformed into amastigotes and after 24 test compounds were added. 
After a 72 h incubation, wells were washed, fixed and Giemsa stained and the infectivity index (% 
of infected macrophages x average number of amastigotes per macrophage) was determined 
microscopically. 
3.3.4 Cytotoxicity assays 
For the citotoxicity test, mammalian kidney fibroblast cells (Vero cell line) were seeded in 96-well 
plates and incubated with test compounds (at micromolar concentration, range 40 µM – 1.5 µM) at 
37°C. The effect of the chalcones was evaluated by the AlamarBlue® assay after 72 h of 
incubation. Absorbance was measured at 550 nm and 630 nm.  
3.3.5 Enzymatic screening   
The ability of the compounds to bind the enzyme trypanothione reductase (TR) was assessed by 
Surface Plasmon Resonance studies whereas the ability to inhibit TR was assessed using 
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spectrophotometric TR assays by following the NADPH oxidation at 340 nm. This part was 
performed by the Institute of Molecular Biology and Pathology of CNR  in Rome. 
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4. Results 
4.1 Study I 
For the first study, 260 samples of blood donors residing in a municipality of the Bologna province 
(ie Valsamoggia) were collected and sent to the CRREM laboratory from 1 April 2014 to 31 March 
2015. The prevalence of asymptomatic infections was evaluated by WB and by real-time PCR. 
Antibody anti-Leishmania were detected by WB in serum of 27 out of 260 blood donors, with a 
seroprevalence of 10.4% (Fig.1). Fifteen out of 27 positive recognized the 16-kD antigen (P16 
band), 10 sera out of 27 recognized the 14-kD antigen (P14 band) and 2 out 27 recognized both the 
specific bands (P14 and P16) (Fig. 3). Following the manufacturers‘ instructions, sera were 
considered WB positive if one band or  both bands were detectable.   
Leishmania DNA was detected by real-time PCR in buffy coat of 4 out of 260 blood donors (Fig 2), 
samples were considered positive when the threshold cycle (CT) value was not higher than 38 
cycles (Fig.4). 
Among the samples positive for Leishmania kDNA, 1 out of 4 corresponded with a positivity to 
anti-Leishmania antibody by WB with the presence on the strip of band P14. In the other three PCR 
cases, no specific antibodies were detected.  
4.2 Study II 
Since 2013, blood samples from patients with a clinical suspicion of VL and resident in the Emilia-
Romagna region were sent to the C.R.R.E.M. laboratory; microbiological diagnosis of VL was 
performed by molecular and serological methods. Samples were kept frozen at –80° after tests 
execution. 
The samples for the study were selected in April 2014 and analyses were performed between June 
2015 and September 2015. 77 serum specimens were chosen, 27 patients were identified as VL 
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cases while in the remaining 50 patients VL was excluded by parasitological and serological 
analysis. The mean age of patients was 44 (range 1 month – 87 years). 51 patients were male (66%), 
26 were female (34%). Fifteen patients were children (range 1 month – 13 years), 12 patients 
(15.6%) were HIV-positive and one patient suffered of  a hematological malignancy in terminal 
stage (Fig.5).  
4.2.1 Performance of the ICT 
The diagnostic performance of the ICTs was low; as shown in Table 1, the sensitivity of ICT1 
(Leishmania Dipstick Rapydtest – APACOR®) was 70%, the sensitivity of ICT2 (Leishmania 
IgG/IgM Combo Rapid Test – CTK Biotech ®) was 63% while ICT3 (Leishmania Strip Quick Test 
– CYPRESS Diagnotics ®) showed the lowest sensitivity, 52%. Specificity was uniformly high for 
all the ICTs (98%). The average of positive predictive value (PPV) and negative predictive value 
(NPV) were 95% and 83%, respectively. When evaluating sera from the five immunocompromised 
VL-positive patients, only one out of 5 tested positive with ICT2 and ICT3, while ICT1 tested 
positive in 2 out of 5 cases. 
Among the VL negative cases, one out of 50 showed a positive result with ICT1 and ICT2. As  the 
patient was not included in the study as a VL case and had no previous history of VL, this result 
was considered as a false positive result . 
4.2.2 Performance of the ELISA  
ELISA showed better performance than ICTs, by exhibiting an average sensitivity of 70%. As 
shown in Table 1, sensitivity of ELISA1 (Leishmania ELISA IgG + IgM – VIRCELL 
Microbiologists®) was 74%, sensitivity of ELISA2 (Leishmania Ab ELISA – CYPRESS 
Diagnotics) was 81%, sensitivity of ELISA3 (Leishmania infantum IgG – ELISA - NOVATECH®) 
and ELISA4 (Leishmania Ab - RIDASCREEN®) was 63%. In contrast, no significant difference 
was found between tests‘ specificity, with an average value of 97%. ELISA1 showed a PPV of 95% 
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and a NPV of 88%, ELISA2 showed a PPV of 100% and the best NPV (91%), ELISA3 showed a 
PPV of 100% and a NPV of 83%, while PPV and NPV values of ELISA4 were significantly lower, 
81% and 82%, respectively. 
Among the immunocompromised VL-positive patients, 2 out of 5 tested positive with all the 
ELISA. 
4.2.3 Performance of the IFAT  
As shown in Table 1, the diagnostic performance of IFAT to identify VL was significantly higher, 
with a sensitivity of 96%, a specificity of 100%, a PPV of 100% and a NPV of 98%.  
Concerning the immunocompromised VL-positive patients, 4 out of 5 tested positive (antibody titer 
> 1/80) or borderline (antibody titer  = 1/80) , the last case exhibited a negative result. 
4.2.4 Performance of the western blot test 
WB test exhibited en excellent sensitivity with a value of 96%,  but modest specificity, with a value 
of 88%; the PPV was 81% and the NPV was 98% (Table 1).  
4.2.5 Comparison of the tests 
The sensitivity of ICTs was modest, with an average value of 62% (Table 1). ELISA showed a 
better performance than ICTs (average sensitivity of 70%), with high fluctuation of sensitivity 
among the 4 different kits (range 63%-81%), ELISA2 exhibited the best performance (81%). 
Conversely, IFAT and WB exhibited en excellent sensitivity, both with a value of 96%. 
The specificity of the tests ranged from 88% to 100% (Table.1). All tests except for WB exhibited 
high specificity values (>92%).  
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The PPV values ranged from 90% to 100% except for WB (81%) and ELISA Ridascreen (81%). 
Conversely, the NPV was lower (range 79%-86%) except for WB, IFAT and ELISA2, respectively, 
98%, 98% and 91% (Table 1). 
By restricting results to immunocompetent patients (n=65), the overall  sensitivity of serological 
tests increased significantly; ICTs range was 59%-77%, ELISA range was 68%-91%, IFAT and 
WB reached a sensitivity of 100% (Table 2). No significantly different specificity-values were  
recorded by restricting results to immunocompetent patients (Table 2). 
The overall sensitivity and specificity of index tests is summarized in Table 1. Sensitivity values 
ranged from 52% to 96%, whereas specificity values ranged from 88% to 100%.  
4.3 Study III 
For the third study, 33 chalcones were obtained through the classic base-catalyzed Claisen-Schmidt 
procedure (as shown in Scheme 1). The A-ring of the chalcone scaffold was properly functionalized 
at the 2 and 4 positions: the C-4 position was occupied by a suitable alkoxy chain namely 3,3-
dimethylallioxy (or prenyloxy) and propargyloxy (O-R), affording series 1 and 2, respectively; the 
C-2 position was differently functionalized by introduction of hydroxy, methoxy, prenyloxy, and 
propargyloxy groups (O-R1). In order to perform a Structure Activity Relationship (SAR) study and 
to explore the chemical space of the target, as B-ring, a pyridine or a substituted aryl function 
bearing some selected substituents (R2) such as methoxy, bromo, nitro, and fluorine were 
introduced (Scheme 2). This part was performed in collaboration with Dr. Belluti from the 
Department of Pharmacy and Biotechnologies (University of Bologna).  
4.3.1 In vitro antileishmanial activity of chalcones 
The in vitro antiparasitic activity of the newly synthetized chalcones against a reference strain of 
L.donovani (MHOM/NP/02/BPK282/0cl4) was determined. Drug susceptibility tests were 
 
 
 
42 
 
implemented on promastigotes at micromolar concentrations (range 40 uM – 1.5 uM) and  the effect 
of the chalcones was evaluated by the AlamarBlue ® assay. The citotoxicity of the chalcones was 
analyzed on mammalian cell line (Vero cell line) by the same assay. 
Compounds 1-33 were tested for their antiparasitic activity against the promastigotes, intracellular 
form of the parasite. Among them, for analogues 17-33 no antileishmanial effect was observed on  
L. donovani promastigotes (Table 4). Derivatives 1-16 turned out to effectively inhibit the parasite 
growth (IC50 was calculated: a value that represent the concentration of a compound that causes 
50% growth inhibition) with variation of the growth rate, ranging from 21.5 µM of the compound 
12 to 3 ± 1.3 μM of the compound 6 (Table 3).  
Considering series 1, the analogues with a simple phenyl function as B-ring and different 
substituents on the 2-position (7, 19-21), were, at the maximum tested dose, inactive with the 
exception of compound 7 which showed a double-digit inhibitory activity (IC50 = 15 µM). In this 
context, the nature of the substituent at the 2-position of the A-ring markedly affected the inhibitory 
behavior; the 2-methoxy-4-prenyloxy substitution pattern proved to be the most favorable and it 
was kept for all the remaining compounds of this series. The presence of a heterocyclic furyl group 
(compound 18) led to a loss of activity while a pyridyl moiety showed interesting IC50 values, 
ranging from 5 μM to 10.5 μM, notably the substituent at the 2-position (hydroxyl or methoxyl) did 
not significantly influenced potencies. The presence of electron-donating moieties such as methoxy 
groups on the B-ring (sub-set of compounds 8, 23, 24), gave different results, as only the bulky 
3,4,5-trimethoxylated analogue 8 proved to inhibit parasite growth with IC50 value of 11 µM. The 
effect of the electron-withdrawing groups namely bromo, nitro, and fluoro (compounds 5, 6, and 22, 
respectively) in the para position was also investigated; compound 6 with the nitro substituent 
resulted to be the most active of all the series as it showed IC50 value in the single-digit micromolar 
range (1.5 µM), followed by the bromo-derivatives compound 5 (IC50 = 16 µM) which resulted 
two-times les active than compound 6.  
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Regarding series 2, the functionalization B-ring gave different results: regarding to the para 
position, the bromo moiety allowed obtaining good antileishmanial agents as compounds 12 and 15, 
the 2-methoxylated and 2-propargyloxylated analogues, respectively, showed micromolar activities 
being as active as compound 5; surprisingly, inactive compounds were obtained with the insertion 
of a nitro substituent (compounds 25 and 26). The same detrimental effects were elicited by the 
3,4,5-trimethoxy substitution pattern (compounds 27, 28). Interestingly, compound 16 turned out to 
effectively inhibit leishmania growth. The pyridine-based subset (compounds 9-11, 13, 14) gave, 
analogously to series 1, excellent results, as low micromolar activities were generally detected. 
In parallel, the cytotoxicity of the molecules was tested using mammalian kidney epithelial cells 
(Vero cell line) for the compounds which have shown any inhibition against promastigotes (1-16). 
Data were expressed as 50% citotoxic concentration (CC50). Moreover the selectivity index (SI) was 
calculated based on CC50 / IC50 ratio. 
The tested compounds generally displayed moderate to very low cytotoxicity. with CC50 values 
superior to 30 µM. In particular, analogues 5, 6, 12 , 15, and 16 were characterized by the absence 
of toxicity that, combined with an effective inhibition of parasite proliferation, led to a promising 
selectivity index (SI). On the contrary, the pyridine-based chalcones, due to their moderate 
cytotoxic effects, showed an unfavorable SI with values ranging from 2 to 3.8. 
These assays allowed to identify two lead molecules, compounds 6 and 16, as the most promising 
of the series. Indeed, these molecules showed a remarkable antileishmanial potency against the 
extracellular form of the parasite (IC50 = 3 ± 1.3 μM and 12.5 ± 2.25 μM, respectively), coupled 
with an excellent SI (above 20). These two compounds were further evaluated on intracellular 
amastigotes of L.donovani in THP-1 cells (human acute monocytic leukemia cells line). Evaluation 
on the inhibition of the growth of the intracellular form of Leishmania confirmed the low 
micromolar trend of inhibition. Notably, compound 16 (IC50 = 4.5 ± 2 μM) was more active than 
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compound 6 (IC50 = 14 ± 7.8 μM) in blocking the growth of amastigotes, highlighting divergent 
abilities in inhibiting promastigote and amastigote growth for the two compounds (Figure 6). 
4.3.2 Evaluation of the Inhibition of trypanothione reductase (TR) 
This part of the study was performed in collaboration with dr. Andrea Ilari from CNR, Institute of 
Molecular Biology and Pathology of Rome. Compound 6 and compound 16 also showed a high 
binding affinity to TR (Kd = 0.6 μM and 2.4 μM, respectively), resulting in an effective enzyme 
inhibition (IC50 = 0.8 μM and 3 μM, respectively). A peculiar feature of this ADPH-dependent 
disulfide oxidoreductase is the presence of cysteine residues in the catalytic triad, which could 
explain the affinity of the compounds for this enzyme. 
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Figure 1 Pie chart representingblood donors that tested positive by  western blot for antileishmanial antibodies. 
 
 
Figure 2 Pie chart representing the blood donors that tested positive by real-time PCR for leishmanial DNA.  
total 260 
positive  27 
total 260 
Positive  4 
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Figure 3 WB strips: nr. 17 a positive case with P14 and P16 band. Nr. 22 a positive sample with P14 band. Nr. 19 low 
positivity of P14 band. Nr 20 a negative sample. 
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Figure 4 Real-time PCR of  (scrivi almeno il gene di Leishmania che vai a testare..).  Amplification plot with β2-
globulin curves (mixed colours), the positive control curve (purple) and a positive curve (blue) from a blood donor 
sample.  
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Figure 5  Age and sex distribution of the VL cases included in Study 2 (n=27) 
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Table 1 Performance of serological tests for VL diagnosis on the study population (n=77) 
 Table 2 Performance of serological tests for VL diagnosis in immunocompetent subjects (n=65) 
  
  
IC 95% 
 
IC 95% 
TEST Sensitivity % LL UL Specificity % LL UL 
ICT 1 70 50 85 96 85 99 
ICT 2 63 42 80 98 88 100 
ICT 3 52 32 71 100 91 100 
ELISA 1 74 53 88 98 88 100 
ELISA 2 81 61 93 100 91 100 
ELISA 3 63 42 80 100 91 100 
ELISA 4 63 42 80 92 80 97 
IFAT 96 80 100 100 91 100 
WB 96 80 100 88 75 95 
 1 
  
IC 95% 
 
IC 95% 
TEST Sensitivity % LL UL Specificity % LL UL 
ICT 1 77 54 91 95 83 100 
ICT 2 73 50 88 98 86 100 
ICT 3 59 37 78 100 90 100 
ELISA 1 82 59 94 98 86 100 
ELISA 2 91 69 98 100 90 100 
ELISA 3 68 45 85 100 90 100 
ELISA 4 68 45 85 91 77 97 
IFAT 100 81 100 100 90 100 
WB 100 81 100 86 71 94 
 1 
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Scheme 1 Reagents and conditions: a) alkylbromide/ K2CO3, acetone, reflux; b) KOH/H2O, EtOH, rt, 18h  
 
 
 
 
 
 
 
Scheme 2 Structure of licochalchone A and General structure of the synthetized compounds 
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Figure 6 Comparison between antipromastigote and antiamastigote activity of compound 6 and compound 16. 
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Table 3 Chemical structure of active compounds, in vitro antileishmanial activity against promastigotes of L. 
donovani, cytotoxicity and selectivity index (SI) of the synthesized compounds  
  
A A4 A3 A2 D
Compound Structure Promastigotes IC₅₀ (µM)¹ Vero CC₅₀ (µM)² SI³
1 5 40 8
2 8.5 32 3.8
3 10.5 32 3
4 10.5 40 3.8
5 16 > 300 > 18.7
6 1.5 > 300 > 200
7 15 100 6.6
8 11 40 3.6
9 17.5 40 2.3
10 4 20 5
11 9.5 20 2.1
12 21.5 > 80 3.7
13 7 20 2.8
14 4 8 2
15 15 > 200 13.3
16 15 > 300 > 20
In vitro activity
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Table 4. Chemical structure of  inactive compounds, in vitro antileishmanial activity against promastigotes of L. 
donovani, cytotoxicity and selectivity index (SI) of the synthesized compounds.  n.i.; Not inhibiting up to 40 µM. n.d.: 
Not determined due to the low antileismanial potency. 
  
Compound Structure Promastigote ( IC50 µM) Vero CC50 (µM) SI
17 n.i. n.d. n.d.
18 n.i. n.d. n.d.
19 n.i. n.d. n.d.
20 n.i. n.d. n.d.
21 n.i. n.d. n.d.
22 n.i. n.d. n.d.
23 n.i. n.d. n.d.
24 n.i. n.d. n.d.
25 n.i. n.d. n.d.
26 n.i. n.d. n.d.
27 n.i. n.d. n.d.
28 n.i. n.d. n.d.
29 n.i. n.d. n.d.
30 n.i. n.d. n.d.
31 n.i. n.d. n.d.
32 n.i. n.d. n.d.
33 n.i. n.d. n.d.
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5. Summary of the studies included in this thesis and general conclusions 
Leishmaniasis is considered an emerging pathogen and as a consequence of global warming, may 
spread in countries previously regarded unfitting for the diffusion of this parasite. In southern 
Europe, leishmaniasis is endemic in different countries such as Spain, Portugal, Greece, France, 
Italy and the Balkans. In the last decades, Leishmania has spread northward (where sandflies were 
previously thought to be absent or present at low densities), as shown by recent reports from 
northern Italy and southern Germany (32-34).  
In this regard, in the last few years, a dramatic increase of VL cases has been reported in the Emilia-
Romagna region in north-eastern Italy, with a cluster of cases in some municipalities, among which 
there is the Valsamoggia district. 
The real prevalence of this parasitic disease is unknown, but it has been demonstrated that the 
majority of infected individuals do not progress to patent leishmaniasis, therefore clinical cases 
usually represent the tip of an ―infection iceberg‖. Nevertheless, even in asymptomatic carriers VL 
can develop because of reactivation from the previous dormant infection; this phenomenon occurs 
mainly upon a heterogeneous collection of medical conditions that hamper the immunological 
control to the parasite. The main cause of Leishmania reactivation is HIV co-infection. while the 
vast majority of non-HIV-related immunosuppressive conditions fall under the realm of 
transplantation medicine, rheumatology and haematology. VL reactivation has been reported after 
different types of organ transplantation, or also associated with the use of various 
immunosuppressive drugs (107). 
Considering the number of individuals at risk of Leishmania reactivation, asymptomatic infection is 
one of the great challenges of the VL disease and several questions remain unresolved regarding 
these asymptomatic infections, for example whether asymptomatically infected persons are 
infectious to the sandflies and which factors can predict the development of VL. Because 
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identification of asymptomatic Leishmania infections is difficult, the  real prevalence of 
asymptomatic carriers in endemic areas is largely unknown and  epidemiological studies are needed 
to answer these questions. 
In our epidemiological study (Study 1), we screened peripheral blood samples obtained from 260 
blood donors living in Valsamoggia, a municipality of the Bologna province where human 
leishmaniasis is endemic. The Leishmania-specific antibodies were revealed by Western blotting in 
the sera of 27 donors (10.4%), which showed the characteristic 14- and/or 16-kDa bands. In 
addition, the presence of the parasitic DNA was evident in the blood of 4 healthy donors (1.5%), 
one of these DNA-positive individuals also showed antileishmanial antibodies. Taking together 
these results, the total prevalence of asymptomatic Leishmania infection in the Valsamoggia 
municipality was 11.5%. This finding suggests a high circulation of the parasite in the Bologna 
area. In line with the literature (108), our study confirm a high proportion of asymptomatic 
Leishmania carriers in endemic areas and how the clinical cases usually represent just the tip of an 
―infection iceberg‖. 
False-positive and false-negative results cannot be excluded when one serological test is used to 
detect Leishmania infection, nonetheless Western blot has excellent sensitivity and specificity (109) 
and false-negative results are rare in our diagnostic experience and according to the literature. 
However, it is known that in asymptomatic carriers antileishmanial antibody titre in serum is low 
and antibodies may be absent (60, 110). According to this, we detected the presence of leishmanial 
DNA in the blood of three healthy donors that tested negative for specific antibodies.  
Concerning molecular test, kDNA real-time PCR is known to be a highly sensitive and specific 
method to detect leishmanial DNA (74, 111). In accordance with the literature, we also 
demonstrated a an excellent sensitivity of this real-time PCR assay for the detection of VL cases 
(REF).  
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The fact that kDNA amplification was negative in 26/27 samples with a positive Leishmania 
serology could be explained by the presence of low parasite density and by the fact that parasitemia 
is probably episodic, hence, few targets were available for PCR amplification.  
The importance of our results lies in the recognition of the presence of cryptic Leishmania infection 
among blood donors. At present, leukocyte depletion is performed in all blood products in Italy, but 
there are not enough evidence that show this is sufficient to prevent the transmission of Leishmania 
with blood transfusion. Leishmania testing is not mandatory in blood banks, but knowledge of 
positive Leishmania serology should impose blood elimination (112). Thus, a broader discussion 
would be required regarding the need to implement specific screening strategies for Leishmania in 
blood donors and to quantify the risk of Leishmania transmission by blood transfusion and by graft  
transplant.  
An additional challenge for VL, due to the limited resources invested, is the lack of 
standardized diagnostic methods. Human leishmaniasis is spreading in Europe and Italy  in areas 
previously considered to be not-endemic or at low endemicity. For example,  the Emilia-Romagna 
region, an endemic region with a low prevalence of cases, assisted to an increased number of 
autochthonous VL cases in the last years (34).  
In this scenario, the need of appropriate diagnostic methods seems mandatory. A few data are 
available about Mediterranean VL and information about diagnostic assays are scarce or relating to 
tropical and subtropical countries with a different socio-economic status compared to our situation.  
For this reason, the aim of Study 2 was to compare the effectiveness of nine commercially available 
serological tests to detect VL cases. These tests were evaluated for diagnostic sensitivity and 
specificity against two different populations, 27 VL positive cases and 50 VL negative subjects 
from the Emilia-Romagna region. 
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In contrast to previous evidences (71, 113), we found that ICTs based on rk39 are less effective than 
other serological tests, showing low sensitivity and specificity. This low performance, compared to 
studies in other countries (i.e. India, Nepal ) (114), could be connected to genetic differences in 
human populations that lead to a strongest or lower host immune response against the antigen used 
in the ICTs. Another explanation for the variable sensitivity of the ICTs in different regions of the 
worls could be attributed to genetic variability of the parasitic strains circulating in different areas 
(115). 
Concerning ELISA, all but one kit exhibited moderate results in terms of sensitivity; conversely, 
IFAT and WB exhibited excellent sensitivity, but low specificity was observed for WB. The reason 
for the lower specificity of WB may be the high efficiency in detecting antileishmanial antibodies, 
also in asymptomatic carriers probably present within the VL-negative group. 
A known obstacle to serodiagnosis of VL is the low antibody response within immunocompromised 
subjects; by restricting the results of serological tests to immunocompetent patients, the average 
sensitivity increased for each assay, with optimal sensitivity of  ELISA 2, IFAT and WB, 91%, 
100%, 100%, respectively. 
It is known that a high sensitivity in serological test is crucial in the diagnosis of VL as missing VL 
diagnosis would lead to patients death. Our study highlights the complexity of VL serodiagnosis; 
the different tests that we evaluated revealed variable diagnostic performance, none of these tests 
appeared to be optimal for the use as screening test, even though ELISA 2 outperforms all of the 
other ELISA tests and ICTs. IFAT and WB showed optimal sensitivity, but their cost and 
complexity in execution would not allow their employment as screening tests, nonetheless these 
tests are recommendable as confirmatory test in the diagnosis of Mediterranean VL or as front line 
tests when the number of samples in the diagnostic routine is limited.  
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Finally, it is important to highlight that when serological results in immunocompromised patients 
are negative, molecular tests are needed before exclusion of VL. 
As leishmaniasis is a neglected disease, treatment options are limited and therapy is often a 
challenge. All currently used first-line and second-line drugs for the treatment of leishmaniasis have 
several drawbacks including cost, toxicity, invasive route of administration and risk of emergence 
of drug resistance. Despite the urgence for the development of new drugs for treating this parasitic 
infection,  a recent study has revealed that during the last 6 years, only one drug has been approved 
for the treatment of leishmaniasis (87). Historically, natural products (NP) are a good strategy when 
searching for new bioactive compounds, as they provide a basis for both design and synthesis of 
derivative compounds that can optimize biological activity and minimize side effects (116). 
Combining the need for new active compounds against leishmaniasis and the known potential of 
natural products to provide chemical structures, which can be used as prototypes for new drugs, 
Study 3 aimed to highlight the use of a group of natural products, ie chalcones, as potential source 
of anti-leishmanial agents. 
Chalcones (1,3-diaryl-2-propen-1-ones), members of the flavonoid family, occupy a special role 
among the biologically active NPs, since the trans-α,β-unsaturated carbonyl function, being a 
Michael acceptor system, could establish covalent linkages with the cysteine residue of a number of 
target proteins. Therefore, chalcones could be regarded as a class of protein-reactive compounds 
and, as expected, they have a large variety of biological activities, including antioxidant, 
antibacterial, antiprotozoal, antimutagenic, antimitotic, antimetastatic, and anti-inflammatory 
activity (117). 
The antiparasitic properties of natural chalcones have been extensively investigated, in particular, 
licochalcone A (Scheme 2), a constituent of roots and rhizomes of various species of Glycyrrhiza L. 
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(licorice root), was found to be endowed with antiparasitic effects namely leishmanicidal and 
antiplasmodial activity (118, 119). 
A series of chalcone analogues with various structural features were prepared based on natural 
product lead and tested for their antileishmanial activity. Among the 33 tested compounds, the 
derivatives from 1 to 16 turned out to effectively inhibit the promastigotes growth in in vitro 
evaluation against L.donovani. In particular, the analogues 6 and 16 were found to be the most 
promising of the series as they showed a remarkable antileishmanial potency against the 
extracellular form of the parasite, coupled with an excellent SI (above 20) and a recognizable 
activity against the amastigote stage of the parasite in L.donovani infected macrophages.  
For pathogens displaying several life stages like Leishmania, there is a need to determine the best 
parasite stage to target. In the case of Leishmania there are two options: first, targeting the 
extracellular living promastigote stage, second, the intracellular amastigote stage. The first option 
meet the reproducibility, rapidity and low cost requirements for high-throughput screenings, due to 
the ease in manipulating promastigotes. The intracellular amastigote stage has been logically 
designated as the more relevant target for primary screening against Leishmania, but methods are 
labor intensive and would not support automation as the required Giemsa staining of infected 
macrophages  is cumbersome as it needs manual counting. Thus, screening against the intracellular 
parasite stage were performed only on the two analogues that showed the best activity against the 
extracellular parasite stage.  
Why compound 16 affects intracellular parasite better than compound 6, in contrast with their 
inhibition on the extracellular parasite stage is not clear, but we can speculate that compound 16 has 
a better host cell-dependent mechanism of action than compound 6. 
Several antileishmanial drugs present a non-specific mode of action that accounts for their high 
toxicity. Thus, the discovery of new chemical entities targeting specific and indispensable 
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components of parasite metabolism is a priority. The thiol-dependent redox metabolism, required 
for DNA synthesis and defense against oxidative stress, is one of the unique metabolic features that 
distinguish trypanosomatids from humans and offer reliable molecular targets for selective drug 
development (120). In the thiol metabolism, it has already been shown that trypanothione reductase 
(TR), an enzyme that belong to the protein family of FAD disulfide oxidoreductases, becomes an 
attractive target for the development of new drugs; our experiments show that TR is strongly 
inhibited in vitro by chalcones, especially by compounds 6 and 16. 
In conclusion, the good inhibition of L.donovani replication the lack of toxicity on human cells and 
the ability to bind and likely inhibit a crucial parasite enzyme such as TR  are all factors that 
highlight the potential for our newly synthetized chalcones to be optimized and developed into more 
specific agents against leishmaniasis. Therefore, efforts will be put to the modification of these 
scaffolds in order to synthetize better antileishmanial chalcones, to try to identify new critical 
targets and additional mechanism of action. 
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